154 related articles for article (PubMed ID: 15910860)
21. Statin treatment and diabetes affect myeloperoxidase activity in maintenance hemodialysis patients.
Stenvinkel P; Rodríguez-Ayala E; Massy ZA; Qureshi AR; Barany P; Fellström B; Heimburger O; Lindholm B; Alvestrand A
Clin J Am Soc Nephrol; 2006 Mar; 1(2):281-7. PubMed ID: 17699218
[TBL] [Abstract][Full Text] [Related]
22. Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure.
Witko-Sarsat V; Friedlander M; Nguyen Khoa T; Capeillère-Blandin C; Nguyen AT; Canteloup S; Dayer JM; Jungers P; Drüeke T; Descamps-Latscha B
J Immunol; 1998 Sep; 161(5):2524-32. PubMed ID: 9725252
[TBL] [Abstract][Full Text] [Related]
23. [Effects of ultrapure water on the levels of oxidative stress and inflammation parameters in maintenance hemodialysis patients].
Zhang Y; Liu J; Tao HQ; Liu ZQ; Tian JW
Nan Fang Yi Ke Da Xue Xue Bao; 2007 Sep; 27(9):1435-7. PubMed ID: 17884796
[TBL] [Abstract][Full Text] [Related]
24. Glyoxalase I deficiency is associated with an unusual level of advanced glycation end products in a hemodialysis patient.
Miyata T; van Ypersele de Strihou C; Imasawa T; Yoshino A; Ueda Y; Ogura H; Kominami K; Onogi H; Inagi R; Nangaku M; Kurokawa K
Kidney Int; 2001 Dec; 60(6):2351-9. PubMed ID: 11737610
[TBL] [Abstract][Full Text] [Related]
25. Positive association between plasma levels of oxidized low-density lipoprotein and myeloperoxidase after hemodialysis in patients with diabetic end-stage renal disease.
Kitabayashi C; Naruko T; Sugioka K; Yunoki K; Nakagawa M; Inaba M; Ohsawa M; Konishi Y; Imanishi M; Inoue T; Itabe H; Yoshiyama M; Haze K; Becker AE; Ueda M
Hemodial Int; 2013 Oct; 17(4):557-67. PubMed ID: 23627905
[TBL] [Abstract][Full Text] [Related]
26. Increased advanced oxidation protein products in Behçet's disease: a new activity marker?
Yazici C; Köse K; Caliş M; DemIr M; Kirnap M; Ateş F
Br J Dermatol; 2004 Jul; 151(1):105-11. PubMed ID: 15270878
[TBL] [Abstract][Full Text] [Related]
27. Oxidation and carboxy methyl lysine-modification of albumin: possible involvement in the progression of oxidative stress in hemodialysis patients.
Mera K; Anraku M; Kitamura K; Nakajou K; Maruyama T; Tomita K; Otagiri M
Hypertens Res; 2005 Dec; 28(12):973-80. PubMed ID: 16671336
[TBL] [Abstract][Full Text] [Related]
28. [Expression of receptors for advanced glycation end products at surface of peripheral blood monocytes and relationship thereof to plasma proinflammatory cytokines in patients undergoing hemodialysis].
Ren H; Hou F; Bi Y; Zhang X
Zhonghua Yi Xue Za Zhi; 2002 Sep; 82(17):1168-72. PubMed ID: 12475402
[TBL] [Abstract][Full Text] [Related]
29. Slow intravenous iron administration does not aggravate oxidative stress and inflammatory biomarkers during hemodialysis: a comparative study between iron sucrose and iron dextran.
Malindretos P; Sarafidis PA; Rudenco I; Raptis V; Makedou K; Makedou A; Grekas DM
Am J Nephrol; 2007; 27(6):572-9. PubMed ID: 17804904
[TBL] [Abstract][Full Text] [Related]
30. Further evidence of inflammation in chronic rheumatic valve disease (CRVD): high levels of advanced oxidation protein products (AOPP) and high sensitive C-reactive protein (hs-CRP).
Chiu-Braga YY; Hayashi SY; Schafranski M; Messias-Reason IJ
Int J Cardiol; 2006 May; 109(2):275-6. PubMed ID: 15946754
[TBL] [Abstract][Full Text] [Related]
31. Soluble receptor for advanced glycation end products in patients with decreased renal function.
Kalousová M; Hodková M; Kazderová M; Fialová J; Tesar V; Dusilová-Sulková S; Zima T
Am J Kidney Dis; 2006 Mar; 47(3):406-11. PubMed ID: 16490618
[TBL] [Abstract][Full Text] [Related]
32. Advanced glycoxidation end products in chronic diseases-clinical chemistry and genetic background.
Kalousová M; Zima T; Tesar V; Dusilová-Sulková S; Skrha J
Mutat Res; 2005 Nov; 579(1-2):37-46. PubMed ID: 16084533
[TBL] [Abstract][Full Text] [Related]
33. Cellular signalling of the receptor for advanced glycation end products (RAGE).
Xie J; Méndez JD; Méndez-Valenzuela V; Aguilar-Hernández MM
Cell Signal; 2013 Nov; 25(11):2185-97. PubMed ID: 23838007
[TBL] [Abstract][Full Text] [Related]
34. Effect of intravenous iron administration frequency on AOPP and inflammatory biomarkers in chronic hemodialysis patients: a pilot study.
Anraku M; Kitamura K; Shintomo R; Takeuchi K; Ikeda H; Nagano J; Ko T; Mera K; Tomita K; Otagiri M
Clin Biochem; 2008 Oct; 41(14-15):1168-74. PubMed ID: 18692036
[TBL] [Abstract][Full Text] [Related]
35. Haemodialysis induces mitochondrial dysfunction and apoptosis.
Raj DS; Boivin MA; Dominic EA; Boyd A; Roy PK; Rihani T; Tzamaloukas AH; Shah VO; Moseley P
Eur J Clin Invest; 2007 Dec; 37(12):971-7. PubMed ID: 18036031
[TBL] [Abstract][Full Text] [Related]
36. Influence of initiation of maintenance hemodialysis on biomarkers of inflammation and oxidative stress.
Pupim LB; Himmelfarb J; McMonagle E; Shyr Y; Ikizler TA
Kidney Int; 2004 Jun; 65(6):2371-9. PubMed ID: 15149350
[TBL] [Abstract][Full Text] [Related]
37. Association between body fat, inflammation and oxidative stress in hemodialysis.
Nihi MM; Manfro RC; Martins C; Suliman M; Murayama Y; Riella MC; Lindholm B; Nascimento MM
J Bras Nefrol; 2010 Mar; 32(1):9-15. PubMed ID: 21448513
[TBL] [Abstract][Full Text] [Related]
38. Nifedipine inhibits advanced glycation end products (AGEs) and their receptor (RAGE) interaction-mediated proximal tubular cell injury via peroxisome proliferator-activated receptor-gamma activation.
Matsui T; Yamagishi S; Takeuchi M; Ueda S; Fukami K; Okuda S
Biochem Biophys Res Commun; 2010 Jul; 398(2):326-30. PubMed ID: 20599709
[TBL] [Abstract][Full Text] [Related]
39. Comorbidity and acute clinical events as determinants of C-reactive protein variation in hemodialysis patients: implications for patient survival.
Snaedal S; Heimbürger O; Qureshi AR; Danielsson A; Wikström B; Fellström B; Fehrman-Ekholm I; Carrero JJ; Alvestrand A; Stenvinkel P; Bárány P
Am J Kidney Dis; 2009 Jun; 53(6):1024-33. PubMed ID: 19394732
[TBL] [Abstract][Full Text] [Related]
40. Genomic damage and circulating AGE levels in patients undergoing daily versus standard haemodialysis.
Fragedaki E; Nebel M; Schupp N; Sebekova K; Völkel W; Klassen A; Pischetsrieder M; Frischmann M; Niwa T; Vienken J; Heidland A; Stopper H
Nephrol Dial Transplant; 2005 Sep; 20(9):1936-43. PubMed ID: 15919695
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
